Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Adamas Pharmaceuticals (ADMS), Hologic (HOLX) and Celyad (CYAD).
Adamas Pharmaceuticals (ADMS)
In a report issued on November 8, Joshua Schimmer from Evercore ISI maintained a Buy rating on Adamas Pharmaceuticals, with a price target of $45.00. The company’s shares closed last Monday at $5.63.
According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 8.9% and a 49.3% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Ionis Pharmaceuticals.
Currently, the analyst consensus on Adamas Pharmaceuticals is a Moderate Buy with an average price target of $18.57, representing a 408.8% upside. In a report issued on November 8, Piper Jaffray also maintained a Buy rating on the stock with a $11.00 price target.
See today’s analyst top recommended stocks >>
Hologic (HOLX)
Canaccord Genuity analyst Mark Massaro maintained a Hold rating on Hologic today and set a price target of $50.00. The company’s shares closed last Monday at $46.56.
According to TipRanks.com, Massaro is a top 100 analyst with an average return of 22.9% and a 62.6% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Orasure Technologies, and Chembio Diagnostics.
Hologic has an analyst consensus of Moderate Buy, with a price target consensus of $55.17, implying a 19.5% upside from current levels. In a report issued on November 8, Leerink Partners also maintained a Hold rating on the stock with a $50.00 price target.
Celyad (CYAD)
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Celyad. The company’s shares closed last Monday at $8.88, close to its 52-week low of $8.10.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 12.0% and a 51.5% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.
Currently, the analyst consensus on Celyad is a Strong Buy with an average price target of $54.00, representing a 479.4% upside. In a report issued on November 6, JonesTrading also reiterated a Buy rating on the stock with a $60.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
